Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091945 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
A Phase 2 study of Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT04091945: Completed Phase 2 study of Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co..
NCT04091945 is a Phase 2 study of Acute Ischemic Stroke that has completed, run by Lumosa Therapeutics Co.. The registered enrollment target is 24 participants, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04091945, a Phase 2 study of Acute Ischemic Stroke, has completed, sponsored by Lumosa Therapeutics Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
Primary Outcome
Compare the the percentage of subject having sICH between LT3001 drug product and Placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LT3001 Drug Product
Study Locations (10)
Other
- Kaohsiung Medical University Chung-Ho Memorial Hospital - Kaohsiung City
- Linkou Chang Gung Memorial Hospital - New Taipei City
- Taipei Medical University - Shuang Ho Hospital - New Taipei City
- China Medical University Hospital - Taichung
- Taichung Veterans General Hospital - Taichung
- Taipei Veterans General Hospital - Taipei
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
New Jersey
- JFK Neuroscience Institute, JFK Medical Center - Edison
Ohio
- The Ohio State University - Wexner Medical Center - Columbus
Tennessee
- Chattanooga Center for Neurologic Research - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 2 |
What the finished NCT04091945 record still lists
NCT04091945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04091945 lists 10 locations in 5 states (Other, Kentucky, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04091945 about?
NCT04091945 is a clinical study titled "A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS". This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
What is the current status of trial NCT04091945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-01-27. Estimated completion is 2021-02-22.
What conditions does trial NCT04091945 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT04091945?
The interventions under investigation include: Placebo (DRUG), LT3001 Drug Product (DRUG).
Who is sponsoring clinical trial NCT04091945?
This trial is sponsored by Lumosa Therapeutics Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04091945 being conducted?
This trial has 10 study locations across Kentucky, New Jersey, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04091945's enrollment target sits among peer trials
24 25th of 25 higher than 1 of 25 other Acute Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI